Drug Chatter -- Tracking biopharma stock chatter

Profile for Medivation, Inc. (MDVN)

« Back to company index

MDVN Chatter Timeline

Stock Ticker for MDVN

Most Active Tweeters for MDVN

UserTweets
@stocknewstimes 1
@SleekMoneycom 1

Recent Tweets for MDVN

SleekMoneycom @SleekMoneycom
Medivation $MDVN Getting Somewhat Favorable Media Coverage, Analysis Finds https://t.co/zr6HFD2E0U
November 8th 2017, 8:11am
stocknewstimes @stocknewstimes
Medivation $MDVN Getting Somewhat Favorable Media Coverage, Analysis Finds https://t.co/Uumayc1iJ7
November 8th 2017, 8:11am
TranscriptDaily @TranscriptDaily
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Stock Price https://t.co/LVvQqkouUi
November 2nd 2017, 4:11pm
TheMarketsDaily @TheMarketsDaily
Medivation $MDVN Receives Coverage Optimism Score of 0.15 https://t.co/x7OM2xE7QB
October 21st 2017, 12:10pm
stocknewstimes @stocknewstimes
Medivation $MDVN Receives Daily News Impact Score of 0.17 https://t.co/N9a11uTjQu
October 15th 2017, 12:10pm
SPNewsAnalysis @SPNewsAnalysis
Medivation $MDVN Receives Daily News Impact Score of 0.17 https://t.co/HWiG0RyyxV
October 15th 2017, 12:10pm
SleekMoneycom @SleekMoneycom
Medivation $MDVN Receives Daily News Impact Score of 0.17 https://t.co/jS6rOpkCEB
October 15th 2017, 12:10pm
specstockscom @specstockscom
Get your say in on $MDVN at SpeculatingStocks, the discovery engine. No login required! #stocks https://t.co/z8u9NlanPH
October 13th 2017, 5:10pm
specstockspulse @specstockspulse
Get your say in on $MDVN at SpeculatingStocks, the discovery engine. No login required! #stocks https://t.co/t94EvCNcHG
October 13th 2017, 5:10pm
portefeuillefun @portefeuillefun
@JohnCendpts That's the "son of Medivation", see @MaverickNY's interview https://t.co/8duJmUh6Uw. $MDVN $JNJ… https://t.co/APHWZnLHFI
October 12th 2017, 6:10am
storminvestor @storminvestor
Medivation $MDVN Receives Media Sentiment Rating of 0.19 https://t.co/i1YodlWlkm
October 9th 2017, 10:10am
SPNewsAnalysis @SPNewsAnalysis
Medivation $MDVN Receives Media Sentiment Rating of 0.19 https://t.co/lhpAUEG0cB
October 9th 2017, 10:10am
midetimes @midetimes
Positive Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Stock Price https://t.co/Ps6ofRc7Nq
October 3rd 2017, 10:10am
dailypoliticaln @dailypoliticaln
Positive Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Stock Price https://t.co/hzuzIrtrLM
October 3rd 2017, 10:10am
dailymailtimes @dailymailtimes
Positive Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Stock Price https://t.co/x84xNuzrqv
October 3rd 2017, 10:10am
WKRBNews @WKRBNews
Positive Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Stock Price https://t.co/cGJT7ByVe2
October 3rd 2017, 9:10am
TheMarketsDaily @TheMarketsDaily
Medivation $MDVN Receiving Somewhat Favorable News Coverage, Report Shows https://t.co/mTfDHcPble
September 27th 2017, 9:09am
YuZhu4 @YuZhu4
RT @FayCortez: Sigh. $AXON $MDVN. Well, at least we & the CEO have been here before. If history repeats, the call is buy: https://t.co/bEMp…
September 26th 2017, 12:09pm
FayCortez @FayCortez
Sigh. $AXON $MDVN. Well, at least we & the CEO have been here before. If history repeats, the call is buy: https://t.co/bEMp51n6TC
September 26th 2017, 10:09am
WilliamGerber1 @WilliamGerber1
With Xtandi $MDVN David Hung changed prostate cancer landscape. But to create illusion of relevance to TNBC he perpetrated dataming "crimes"
September 25th 2017, 9:09am
megtirrell @megtirrell
RT @FayCortez: Not perfect but better: $AXON v $MDVN days before Alzheimer's data. Same CEO. Same disease. Same run. Hopefully different ou…
September 21st 2017, 8:09pm
FayCortez @FayCortez
Not perfect but better: $AXON v $MDVN days before Alzheimer's data. Same CEO. Same disease. Same run. Hopefully dif… https://t.co/Lm1YLxrMmq
September 21st 2017, 3:09pm
YuZhu4 @YuZhu4
RT @FayCortez: One is $MDVN leading up to Dimebon. One is $AXON this month. I wish I could superimpose them. https://t.co/LLggHvsETn
September 21st 2017, 3:09pm
FayCortez @FayCortez
One is $MDVN leading up to Dimebon. One is $AXON this month. I wish I could superimpose them. https://t.co/LLggHvsETn
September 21st 2017, 3:09pm
IRAMarketReport @IRAMarketReport
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Medivation $MDVN Share Price https://t.co/JYoTQRrEmo
September 21st 2017, 10:09am
chaffeybreeze @chaffeybreeze
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Medivation $MDVN Share Price https://t.co/Vi8kVgpjq6
September 21st 2017, 10:09am
BigChodu @BigChodu
@stb8444 It was expensive buyout... $MDVN was priced same price tag with Xtandi + PARP But whatever, ignited biotech bull market.
September 17th 2017, 10:09pm
TheMarketsDaily @TheMarketsDaily
Medivation $MDVN Given Daily Media Sentiment Score of 0.18 https://t.co/6eVAZWe9k4
September 15th 2017, 9:09am
BioGraphica1 @BioGraphica1
What if a second drug gets approved? $MDVN parp-i? Then you may have actually UNDERestimated revenues…
September 14th 2017, 2:09am
WatchlistN @WatchlistN
Medivation $MDVN Receiving Somewhat Favorable Media Coverage, Analysis Finds https://t.co/965YwSaNBN
September 9th 2017, 9:09am
SleekMoneycom @SleekMoneycom
Analyzing Medivation $MDVN and Intercept Pharmaceuticals $ICPT https://t.co/SmHryi2Fyu
September 9th 2017, 12:09am
echo_nyc @echo_nyc
This is a good article... https://t.co/RUvH4c5l4k But remember the fate of Ahab (Spoiler!) was not exactly the payout David got from $MDVN
September 8th 2017, 10:09am
RebeccaDRobbins @RebeccaDRobbins
Read about $MDVN's Dimebon Alz failure 2x in 2 days in @statnews, from @damiangarde (https://t.co/JLjqxKN1C3) & me (https://t.co/3a9MJeMj1j)
September 8th 2017, 9:09am
bnbdailynews @bnbdailynews
Comparing Medivation $MDVN & Summit Therapeutics PLC $SMMT https://t.co/5LRH6K7BtC
September 6th 2017, 2:09am
DrPaulyDeSantis @DrPaulyDeSantis
@megtirrell Love reading these SEC filings, looks very similar to bidding process/value increases for $MDVN $PFE deal
September 5th 2017, 6:09pm
TickerReport @TickerReport
Medivation $MDVN Receives Daily News Impact Rating of 0.00 https://t.co/OMAdablbvD
September 3rd 2017, 9:09am
TickerReport @TickerReport
Medivation $MDVN Receives Daily News Impact Rating of 0.00 https://t.co/J1DUp7orod
September 3rd 2017, 9:09am
emq_news @emq_news
Medivation $MDVN Receives Daily News Impact Rating of 0.00 https://t.co/GMZZA6q3Ps
September 3rd 2017, 9:09am
chaffeybreeze @chaffeybreeze
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Medivation $MDVN Stock Price https://t.co/U6FdNgZbsJ
August 28th 2017, 9:08am
IRAMarketReport @IRAMarketReport
Somewhat Positive Media Coverage Somewhat Unlikely to Affect Medivation $MDVN Stock Price https://t.co/5PN0ig3Kbt
August 28th 2017, 9:08am
bnbdailynews @bnbdailynews
Contrasting Intercept Pharmaceuticals $ICPT and Medivation $MDVN https://t.co/GaOEDfrwnx
August 27th 2017, 11:08am
ZolmaxNews @ZolmaxNews
Contrasting Intercept Pharmaceuticals $ICPT and Medivation $MDVN https://t.co/JUZaL7aVxn
August 27th 2017, 10:08am
StockNewsWires @StockNewsWires
$PFE $MDVN: Myovant Sciences: Near-Term Catalyst And Long-Term Promise: https://t.co/aBxKymtDIy
August 25th 2017, 9:08am
BayAreaBiotechI @BayAreaBiotechI
How many examples are there where a drug works in >2L and then moves to 1L and huge value is realized? Seems easy $MDVN $GEN
August 24th 2017, 11:08am
midetimes @midetimes
Financial Review: Medivation $MDVN vs. Summit Therapeutics PLC $SMMT https://t.co/PjIN8X1aRZ
August 22nd 2017, 9:08am
WKRBNews @WKRBNews
Financial Review: Medivation $MDVN vs. Summit Therapeutics PLC $SMMT https://t.co/yQhhtbPXnE
August 22nd 2017, 9:08am
dailypoliticaln @dailypoliticaln
Financial Review: Medivation $MDVN vs. Summit Therapeutics PLC $SMMT https://t.co/kwsLGWzlXJ
August 22nd 2017, 9:08am
chaffeybreeze @chaffeybreeze
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Share Price https://t.co/XVD0vqDOfO
August 22nd 2017, 6:08am
IRAMarketReport @IRAMarketReport
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Medivation $MDVN Share Price https://t.co/KV3CCGQ7Xr
August 22nd 2017, 6:08am

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.